The Fox Chase Cancer Center (FCCC) demonstrates a continued commitment to clinical cancer research through administrative and scientific involvement with the Eastern Cooperative Oncology Group (ECOG). Participation in the ECOG clinical research programs is an integral component of the cancer research performed at FCCC. Active participation in ECOG activities provides an opportunity for our patients to participate in controlled multidisciplinary trials which are designed to provide the best potential new therapies for a variety of different types of cancer. In turn, FCCC performs an important role in defining the merits of these new therapies. ECOG also provides an important opportunity for the Developmental Therapeutics Molecular Medical program at our Center to interact with a larger number of clinical investigators interested in testing new and innovative therapies to improve survival and increase the cure rate for many different cancers. The Cooperative Group Outreach Program (CGOP) provides the opportunity to support our active affiliates, and their critical data management and nurse oncology functions. Through this program we make available to the community the most current therapeutic options and in turn these treatments are tested in the environment in which they will be most widely applied. The primary objectives of this grant are to (1) maintain a level of accrual to ECOG studies;(2) increase the level of multidisciplinary involvement by integrating key modality-oriented individuals into ECOG activity In our affiliate institutions;(3) Increase our contribution to the scientific activities of ECOG, and (4) maintain a high level of scientific and administrative Involvement In ECOG programs. During the next 6 year period, we anticipate growth In our ECOG accrual and In the impact we have on the scientific activities of the Group.
The funding of this grant to Fox Chase Cancer Center (FCCC) provides opportunities for advancement of novel therapeutics to be evaluated in controlled clinical trials. The Eastern Cooperative Oncology Group (ECOG) is the sum of its component cancer center members. The scientific rationale, protocol development and accrual depend on the contribution of the investigators at FCCC. Taken together this will promote the development of new therapies to improve the outcomes for patients with malignancies.
|Sanford, Stacy D; Zhao, Fengmin; Salsman, John M et al. (2014) Symptom burden among young adults with breast or colorectal cancer. Cancer 120:2255-63|
|Tevaarwerk, Amye J; Gray, Robert J; Schneider, Bryan P et al. (2013) Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 119:1140-8|
|Landry, Jerome; Catalano, Paul J; Staley, Charles et al. (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101:587-92|
|Chung, Christine H; Seeley, Erin H; Roder, Heinrich et al. (2010) Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev 19:358-65|
|Lara Jr, Primo N; Natale, Ronald; Crowley, John et al. (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530-5|
|Koch, Wayne M; Ridge, John A; Forastiere, Arlene et al. (2009) Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614. Arch Otolaryngol Head Neck Surg 135:851-8|
|Blanke, Charles D; Rankin, Cathryn; Demetri, George D et al. (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-32|
|Heinrich, Michael C; Owzar, Kouros; Corless, Christopher L et al. (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Gr J Clin Oncol 26:5360-7|
|Goldstein, Lori J; O'Neill, Anne; Sparano, Joseph A et al. (2008) Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 26:4092-9|
|Ignatoff, Jeffrey M; Chen, Yu-Hui; Greenberg, Richard Evan et al. (2008) Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group. Urol Oncol :|
Showing the most recent 10 out of 31 publications